Visterra, Inc.

The General Hospital Corporation

Boopathy Ramakrishnan

Zachary Shriver

Karthik Viswanathan

Andrew M Wollacott

Gregory Babcock

James R Myette

Hedy Adari-Hall

Brian Booth

Obadiah Joseph Plante

Lauren Olinski

Scott Moore Carlson

James C Delaney

Bharat Chaganty

Kristin Narayan

Hamid Tissire

Kenneth Douglas Johnson

Tyree J Koch

Kai Li

Thiago De Jesus Borges

Leonardo Vidal Riella

Zachary Holmes Shriver

Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Antibody molecules to C5AR1 and uses thereof

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Humanized antibody molecules to CD138 and uses thereof

IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.

Interleukin-2 agents and uses thereof

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Humanized complement 5a receptor 1 antibodies and methods of use thereof

Humanized complement 5A receptor 1 antibodies and methods of use thereof

Methods of using interleukin-2 agents

Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Antibody molecule-drug conjugates and uses thereof

Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Antibody molecules to CD138 and uses thereof

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Growing community of inventors

Braintree, MA, United States of America

Boopathy Ramakrishnan